Marinomed Biotech AG | WebDisclosure

Basculer en Français

8296	Companies
114899	Keywords
55318	Articles
62453	Press releases

Home
Companies
Marinomed Biotech AG

BRIEF

published on 10/08/2024 at 07:50, 1 month 13 days ago

Marinomed Biotech AG annonce des résultats d'essais positifs pour les gouttes ophtalmiques au tacrolimus

Essai Clinique Marinosolv Biodisponibilité Tacrosolv Conjonctivite Allergique
PRESS RELEASE

published on 10/08/2024 at 07:45, 1 month 13 days ago

Marinomed Biotech AG publishes remarkable results showing alleviation of allergic eye inflammation in patients treated with Tacrolimus eye drops in peer-reviewed journal
Marinomed Biotech AG publishes study results on Tacrolimus eye drops, showing significant alleviation of allergic eye inflammation. Potential treatment for inflammatory eye diseases

Marinomed Biotech AG Study Results Ocular Surface Tacrolimus Eye Drops Allergic Eye Inflammation
BRIEF

published on 09/24/2024 at 07:50, 1 month 27 days ago

Marinomed Biotech AG annonce des résultats cliniques positifs pour ses gouttes oculaires uniques à base de carraghénane

Marinomed Biotech AG Résultats Cliniques Carraghénose Gouttes Pour Les Yeux Syndrome De L'œil Sec
BRIEF

published on 09/24/2024 at 07:50, 1 month 27 days ago

Marinomed Biotech AG Reports Positive Clinical Results for Unique Carragelose Eye Drops

Marinomed Biotech AG Carragelose Clinical Results Eye Drops Dry Eye Syndrome
PRESS RELEASE

published on 09/24/2024 at 07:45, 1 month 27 days ago

Marinomed Biotech AG reports positive clinical results for unique Carragelose eye drops
Marinomed Biotech AG reports positive clinical results for Carragelose eye drops, improving dry eye symptoms by 54%. The eye drops are well tolerated and hold valid Medical Device Directive certificate

Marinomed Biotech AG Carragelose Clinical Results Dry Eye Eye Drops
BRIEF

published on 09/18/2024 at 17:26, 2 months 2 days ago

Marinomed Biotech AG Announces Capital Increase Excluding Subscription Rights

Investors Capital Increase Marinomed Biotech AG Subscription Rights Issue Price
BRIEF

published on 09/18/2024 at 17:26, 2 months 2 days ago

Marinomed Biotech AG annonce une augmentation de capital hors droits de souscription

Augmentation De Capital Investisseurs Marinomed Biotech AG Droits De Souscription Prix D'émission
PRESS RELEASE

published on 09/18/2024 at 17:21, 2 months 2 days ago

EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share
Marinomed Biotech AG resolves capital increase by issuing 154,053 bearer shares at EUR 5 per share, excluding statutory subscription rights

Capital Increase Marinomed Biotech AG Subscription Rights Bearer Shares EUR 5
BRIEF

published on 09/15/2024 at 17:54, 2 months 5 days ago

Marinomed Biotech AG Sets Price Range for Capital Increases

Capital Increase Restructuring Share Price Investor Negotiations Marinomed Biotech
BRIEF

published on 09/15/2024 at 17:54, 2 months 5 days ago

Marinomed Biotech AG fixe une fourchette de prix pour ses augmentations de capital

Augmentation De Capital Restructuration Cours De L'action Biotechnologie Marinomed Négociations Avec Les Investisseurs

Accesswire

Published on 11/21/2024 at 13:00, 15 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 15 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 15 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 15 minutes ago

Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 15 minutes ago

Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 12:35, 39 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 8 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 14 minutes ago

Holding(s) in Company
Published on 11/21/2024 at 11:30, 1 hour 45 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 17 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 17 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 17 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 17 hours 7 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 55 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE